CGON CG Oncology, Inc.
Price Chart
Executive Summary
CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, wider than the prior year's $0.45 loss, and total revenue of $1.1M. The key positive was a BLA submission timeline update for cretostimogene in HR BCG-unresponsive NMIBC, now expected to complete in Q4 2026, and a strong cash position of $1.1B. However, the widening net loss and lack of consensus estimates for this quarter make the financial results directionally negative for a pre-revenue biotech.
Actionable Insight
The stock will trade on the PIVOT-006 topline data and CORE-008 Cohort CX results expected in the coming weeks, not on the quarterly financials. The BLA completion timeline extension to Q4 2026 removes near-term regulatory catalyst risk but provides clarity. Monitor the AUA presentation on May 16 for the first combination data with gemcitabine.
Key Facts
- BLA completion for cretostimogene in HR BCG-unresponsive NMIBC expected Q4 2026, following FDA alignment discussions
- PIVOT-006 Phase 3 topline data in intermediate-risk NMIBC anticipated H1 2026
- CORE-008 Cohort CX Phase 2 first results to be presented at AUA 2026 on May 16
- Cash, cash equivalents and marketable securities of $1.1B as of March 31, 2026, up from $742.2M at Dec 31, 2025
- Net loss of $60.2M ($0.71/share) for Q1 2026 vs $34.5M ($0.45/share) in Q1 2025
- R&D expenses increased to $43.7M from $27.5M; G&A expenses increased to $20.8M from $14.8M
- Raised $391.4M net proceeds from ATM facility in Q1 2026, selling 6,941,407 shares
- Total revenues of $1.1M for Q1 2026 vs $52K in Q1 2025, primarily from commercial and development revenue
Financial Impact
Net loss widened by 74.7% YoY to $60.2M; cash position strengthened by $334M sequentially to $1.1B
Risk Factors
- PIVOT-006 Phase 3 topline data may miss efficacy or safety endpoints
- BLA submission delay beyond Q4 2026 could push potential approval into 2027
- Widening net losses with no near-term revenue visibility; cash burn rate increased to ~$60M/quarter
- Dilution risk from continued ATM usage (6.9M shares sold in Q1 2026)
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-213440 |
| Document: ck0001991792-20260508.htm | 0001193125-26-213440 |
| Document: 0001193125-26-213440-index-headers.html | 0001193125-26-213440 |
| Document: 0001193125-26-213440-index.html | 0001193125-26-213440 |
| Document: 0001193125-26-213440.txt | 0001193125-26-213440 |
| 8-K Data (Synthetic) | 0001193125-26-213440 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
14d ago
|
8-K
| $61.89 $59.23 | ▼ −4.30% | ▼ −5.38% | $54.40 (−12.10%) |
|
May 15, 2026
25d ago
|
Press Release
| $66.93 $64.25 | ▼ −4.00% | ▼ −4.97% | $54.40 (−18.72%) |
|
May 8, 2026
4w ago
|
8-K
| $69.62 $69.54 | ▼ −0.12% | ▼ −1.59% | $54.40 (−21.86%) |
|
May 8, 2026
4w ago
|
Press Release
| $69.62 $69.54 | ▼ −0.12% | ▼ −1.59% | $54.40 (−21.86%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $66.82 $67.70 | ▲ +1.32% | ▲ +0.92% | $54.40 (−18.59%) |
|
Apr 17, 2026
7w ago
|
144
| $70.40 $66.82 | ▼ −5.09% | ▼ −6.00% | $54.40 (−22.73%) |
|
Apr 13, 2026
8w ago
|
8-K
| $67.70 $70.40 | ▲ +3.99% | ▲ +0.69% | $54.40 (−19.65%) |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $57.76 $61.29 | ▲ +6.11% | ▲ +7.32% | $54.40 (−5.82%) |
|
Feb 27, 2026
14w ago
|
Press Release
| $58.80 $61.88 | ▲ +5.24% | ▲ +7.22% | $54.40 (−7.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access